Please use this identifier to cite or link to this item:
|Title:||Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats|
|Author:||Busquets i Rius, Sílvia|
Toledo Soler, Míriam
López-Soriano, Francisco J.
Argilés Huguet, Josep Ma.
Factors de transcripció
|Abstract:||Cachexia is a common systemic manifestation. Additionally, myostatin is known to be a negative regulator of skeletal muscle development. The present study aimed to investigate whether formoterol down-regulates the myostatin system in skeletal muscle of tumour-bearing rats. Real-time PCR and Western blotting were used for the analysis. Results showed that rats bearing the Yoshida AH-130 ascites hepatoma, a cachexia-inducing tumour, exhibited marked muscle wasting that affected the mass of the muscles studied. The cachectic animals exhibited a significant increase in the mRNA levels of the myostatin receptor (ActIIB) in gastrocnemius muscles. Notably, the expression of the various forms of follistatin, a protein with the opposite effects to those of myostatin, was significantly reduced as a result of the implantation of the tumour. When the animals were treated with formoterol, a β-agonist with anti-cachectic potential, increases in skeletal muscle weights were observed. The β-agonist significantly increased levels of various follistatin isoforms and significantly decreased the expression levels of the myostatin receptor. In addition, formoterol treatment resulted in a significant decrease of the myostatin protein content of the gastrocnemius muscle. In conclusion, the results presented indicate that certain anabolic actions of formoterol on the skeletal muscle of cachectic animals may be mediated via the myostatin system.|
|Note:||Reproducció del document publicat a: http://dx.doi.org/10.3892/ol.2011.442|
|It is part of:||Oncology Letters, 2010, vol. 3, num. 1, p. 185-189|
|Appears in Collections:||Articles publicats en revistes (Bioquímica i Biomedicina Molecular)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.